Jane Street Group LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Jane Street Group LLC purchased a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,907 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors have also made changes to their positions in the company. Rhumbline Advisers acquired a new stake in shares of Eliem Therapeutics during the 2nd quarter valued at about $59,000. SG Americas Securities LLC bought a new stake in shares of Eliem Therapeutics during the third quarter valued at approximately $60,000. Valence8 US LP acquired a new position in shares of Eliem Therapeutics in the 3rd quarter valued at $61,000. Chicago Partners Investment Group LLC acquired a new position in shares of Eliem Therapeutics in the 3rd quarter valued at $81,000. Finally, Dimensional Fund Advisors LP acquired a new position in Eliem Therapeutics in the 2nd quarter worth $89,000. 69.76% of the stock is owned by hedge funds and other institutional investors.

Eliem Therapeutics Price Performance

Shares of NASDAQ ELYM opened at $1.87 on Thursday. The business has a 50-day moving average of $2.72 and a 200-day moving average of $5.12. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55. The stock has a market capitalization of $55.64 million, a price-to-earnings ratio of -3.53 and a beta of -0.39.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.